ACHC Price Prediction Next Week
Analysis and Insights
News Analysis:
Acadia Healthcare (ACHC) has experienced significant news-related volatility. On March 1, 2025, the stock dropped 25.53% due to disappointing fourth-quarter earnings, where net income fell 44% year-over-year, despite a 4.2% increase in revenues. The company also announced the pricing of $550 million in senior notes due 2033, which may indicate efforts to strengthen its balance sheet.
Technical Analysis:
The stock is currently trading near its Fibonacci S1 support level of $28.03, with a pivot point at $29.49. The Relative Strength Index (RSI) is at 25.61, indicating oversold conditions, while the MACD is negative, suggesting bearish momentum.
Fibonacci Levels:
The Fibonacci levels indicate that ACHC is near a critical support zone, with the S1 level at $28.03 and the pivot point at $29.49.
{FIBONACCI:symbol=ACHC.O, type=0}
Analyst Sentiment:
Analysts have maintained a Moderate Buy consensus on ACHC, with a price target of $48.78, implying significant upside potential.
Conclusion:
Given the oversold RSI and proximity to Fibonacci support levels, ACHC may experience a short-term rebound. However, the overall bearish trend and negative MACD suggest caution.
Prediction: The stock is expected to trade between $28.03 and $30.50 next week. A cautious buy recommendation is given, with a target price of $30.50.
ACHC Similar Chart Price Prediction
The price of ACHC is predicted to go up -10.64%, based on the high correlation periods with VERV. The similarity of these two price pattern on the periods is 99.44%.
ACHC
VERV
Down: -10.64%Similarity: 99.44%
ACHC Revenue Forecast
ACHC EPS Forecast
ACHC FAQs
What is ACHC revenue forecast for next quarter？
What is ACHC eps forecast for next quarter？
ACHC Analyst's Forecast
Ben Hendrix
RBC Capital
Buy
2025-03-03
Price Target
$64 → $43
Upside
+46.43%
RBC Capital lowered the firm's price target on Acadia Healthcare to $43 from $64 and keeps an Outperform rating on the shares after its Q4 earnings miss. The stock fell off on Friday followed weaker than expected 2025 guidance, with an EBITDA range below the firm's Street-low estimate, as well as a revised multi-year outlook suggesting a notable reset of intermediate-term margin expectations, the analyst tells investors in a research note. The firm remains at Outperform on "atypically depressed" valuation, but also "feels less inclined" at this point to demand a premium to historical acute care hospital multiples, RBC added.
Matthew Gillmor
Keybanc
Buy
2025-03-03
Price Target
$70 → $65
Upside
+121.35%
Ryan Langston
TD Cowen
Strong Buy
2025-01-07
Price Target
$70 → $66
Upside
+45.66%
